Prețul acțiunilor Moderna s-a dublat după prezentarea unui vaccin experimental pentru cancer

Moderna's stock price surged after positive results from a cancer vaccine trial developed with Merck. The personalized mRNA vaccine showed significant efficacy in preventing melanoma recurrence. The study involved over 1,100 patients and combined the vaccine with Merck's Keytruda immunotherapy. Initial findings indicate improved patient outcomes compared to Keytruda alone, with plans for further evaluation and potential future applications in other cancers.